No description available.

Chronic posterior uveitis is a relatively common clinical disorder and an importance cause of visual impairment in young adults. Experimental autoimmune uveitis (EAU) and its associated experimental autoimmune pinealitis (EAP) induced by retinal autoantigens are predominantly CD4+ T cell mediated (auto) immune disease of the retina and uveal tract of the eye and the pineal gland respectively. EAU bears a close clinical and pathological resemblance to chronic posterior uveitis in humans and seves as a good animal model for the study of posterior uveitis. The EAU model was used to study means of modulating the host's immune response to suppress or inhibit the onset of uveitis. The onset of retinal S-antigen induced EAU could be successfully inhibited by pre-treating Lewis rats with a retinal S-antigen (carboxy terminus) specific monoclonal antibody called S2.4.C5. This however did not suppress the associated EAP indicating that the monoclonal antibody acted via the efferent arc of the immune mediated response. This prompted a study of the 'Blood-retinal and Blood-pineal barrier sites' during the active stages of EAU and EAP. Transmission electron microscopy of the vascular endothelium revealed changes resembling 'High endothelial venules' of lymph nodes in the retinal and pineal vasculature. In an attempt to identify one or more immunodominant epitopes of S-antigen that may be relevant to tolerance induction, an in-vitro and in-vivo study using enzyme digested preparations of S-antigen was carried out. This revealed that digestion of S-antigen by a protease derived from staphylococcus aureus V8 strain, not only inhibited the binding of the monoclonal S2.4.C5 in-vitro but was also associated with an in-vivo attenuation of the pathogenic response to S-antigen indicating that a dominant immunogenic epitope of S-antigen was located at the C-terminus of the molecule.

Thesis (doctoral)--Rijksuniversiteit te Utrecht.

Thesis (doctoral)--Rijksuniversiteit te Utrecht.

Excerpt: Approximately 1 week after having been shot in the left eye with a foam dart from a toy gun, a 37-year-old woman presented to an optometrist due to persistent pain in the eye.

No description available.

No description available.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 4 uppsatser.

DE LA TESIS:Se trata de un estudio observacional no controlado, de 120 pacientes afectos de melanoma uveal, tratados todos ellos con braquiterapia con semillas de Yodo-125, a los que se les ha efectuado un seguimiento desde el punto de vista oftalmológico, durante al menos un año. El objetivo principal de la tesis fue determinar los factores que influyen en la evolución de la agudeza visual tras la aplicación de dicho tratamiento, y la descripción de un modelo matemático que pueda explicar la evolución de dicha variable clínica oftalmológica.Tras la finalización del estudio, se observó que la pérdida de agudeza visual de forma significativa está en relación con las variables: dosis administrada en la mácula, dosis administrada en el cristalino y tiempo de seguimiento tras el tratamiento. Esta relación se concreta en la fórmula siguiente:AV final= Av basal+Tiempo+Dosis Mácula+Dosis mácula*Tiempo

A Braquiterapia oftálmica utiliza radionuclídeos, como o Rutênio-106 no tratamento de melanomas uveais e outras neoplasias oculares. Para realização desse procedimento é necessária uma interação da equipe multidisciplinar principalmente entre a Oftalmologia, Oncologia, Radioterapia, Física Médica e Enfermagem, envolvendo estrutura física e profissionais qualificados para garantir os processos e resultados do procedimento. Este estudo tem o objetivo de avaliar os primeiros tratamentos de braquiterapia oftálmica com Rutênio-106 e também estabelecer protocolos e processos para implementação da técnica em um Hospital Geral. Os resultados obtidos para os primeiros 11 casos tratados entre 2015 e 2017, sendo 10 melanomas e 1 hemangioma, evidenciaram baixa toxicidade aguda. Foram analisados 5 pacientes com seguimento de 5 a 13 meses. Houve regressão da lesão em todos os pacientes, com média de 28% no ápice e 12% na base no período de até 12 meses, sendo observado uma regressão progressiva durante o período de avaliação. Os protocolos foram utilizados e validados durante todas as etapas do tratamento. O uso do Ru-106 mostra-se alternativa viável no tratamento de lesões oculares, sendo primordial a capacitação e integração da equipe e seguimento de protocolos para o êxito do tratamento. / Ophthalmic Brachytherapy uses radionuclides, such as Ruthenium-106 in the treatment of uveal melanomas and other ocular tumors. For this procedure is necessary a multidisciplinary interaction between Ophthalmology, Oncology, Radiotherapy, Medical Physics and Nursing, involving physical structure and qualified professionals to guarantee the processes and results of the procedure. This study aims to evaluate the first ophthalmic brachytherapy treatments with ruthenium- 106 and also to establish protocols and processes for the implementation of this service in a General Hospital. The results obtained for the first 11 cases treated between 2015 and 2017, being 10 melanomas and 1 hemangioma, showed low acute toxicity. Five patients were followed up for 5 to 13 months. There was regression of the lesion in all of these patients, with a mean of 28% at the apex and 12% at the base in the period close to 1 year, with a progressive regression during the evaluation period. The protocols were used and validated during all stages of treatment. The use of 106-Ru is a viable alternative in the treatment of ocular tumors, being the team qualification and the correct follow-up of the protocols crucial for the treatment success.